How Well Does the ADAS-Cog Measure the Spectrum of Alzheimer’s Disease Severity?

Jared F. Benge12, Steve Balsis3, Paul J. Massman24, Rachelle S. Doody2

1Michael E. DeBakey VA Medical Center, 2Baylor College of Medicine, 3Texas A & M University, 4University of Houston,

BACKGROUND

The ADAS-cog is the most frequently used measure in clinical trials of Alzheimer’s disease (AD) medications. Despite its widespread use, little is known about the psychometric properties of the ADAS-cog subscales. The purpose of the current study was to use Item Response Theory analyses to determine how the ADAS-cog subscales perform across the spectrum of AD related cognitive impairment.

METHODS (CONT.)

PROCEDURE

Patients underwent full neurological and neuropsychological evaluations at baseline and yearly. As part of this larger protocol, patients were administered the ADAS-cog by trained psychometricians. The most recent ADAS-cog scores were selected for the current study to allow for the inclusion of a broad range of dementia severity in the analysis.

DATA ANALYSIS

The analyses were conducted within an Item Response Theory (IRT) framework. IRT analyses allow for the evaluation of how items perform across the spectrum of a latent variable. Thus, in the current study we could evaluate the relationship of observed scores to latent cognitive impairment in AD.

RESULTS AND DISCUSSION

1. The magnitude of dementia severity represented by each point on the ADAS-cog is not equal across the scale. A 3-point difference can represent an actual difference of dysfunction of anywhere from .70 SDs to .14 SDs of disease severity.

2. Subtests tended to provide maximum information at more moderate stages of dementia severity.

3. Only performance on the immediate free recall task measured AD well at mild stages of the disease. Using IRT, other measures (e.g., delayed recall) may be added that are sensitive to mild AD, thus allowing the ADAS-cog to provide more information at very mild levels of the disease.

Acknowledgements: This study was supported by a Mitchell Foundation Alzheimer’s Disease Research Pilot Grant (JB, SB, PM) and the Cain Foundation (RD).

CONTACT: BALSIS@TAMU.EDU OR JARED.BENGE@VA.GOV